Format

Send to

Choose Destination
Curr Opin Clin Nutr Metab Care. 2011 Jul;14(4):334-40. doi: 10.1097/MCO.0b013e328347924a.

Intestinal microbiota in inflammation and insulin resistance: relevance to humans.

Author information

1
EA4466, Département de Biologie Expérimentale, Métabolique et Clinique, Faculté des Sciences Pharmaceutiques Paris Descartes, Clinical Chemistry, Cochin-Broca-Hotel Dieu, APHP, Paris, France. jean-pascal.de-bandt@parisdescartes.fr

Abstract

PURPOSE OF REVIEW:

The gut microbiota is a very complex ecosystem which interacts extensively with the host, influencing multiple metabolic and physiological functions. Several diseases have been shown to be associated with specific alterations in gut microbiota. It is more and more underscored as playing a major role in the development of insulin resistance and inflammation associated with excess weight gain.

RECENT FINDINGS:

Recent studies in obese patients have shown perturbations in gut microbiota with a weight gain-associated increase in the Firmicutes/Bacteroidetes ratio ameliorated by various attempts at inducing weight loss.

SUMMARY:

Intestinal microbiota may contribute to the development of inflammation and insulin resistance by two main mechanisms. First, gut microbiota might facilitate energy harvest from the gut leading via perturbation in energy homeostasis to fat deposition and increased adipokine production and plasma free fatty acid levels both contributing to insulin resistance and inflammation. Alternatively, it can initiate an inflammatory process either originating from the intestine or generated at the peripheral level via endotoxin leakage into the blood from the intestine, both leading secondarily to insulin resistance.

PMID:
21587065
DOI:
10.1097/MCO.0b013e328347924a
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center